Clean Yield Group Grows Position in Hologic, Inc. (NASDAQ:HOLX)

Clean Yield Group increased its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 18.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 45,646 shares of the medical equipment provider's stock after acquiring an additional 7,266 shares during the period. Clean Yield Group's holdings in Hologic were worth $3,291,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wolff Wiese Magana LLC purchased a new stake in Hologic during the third quarter valued at about $25,000. General Partner Inc. bought a new stake in Hologic in the 4th quarter worth $26,000. First Horizon Advisors Inc. grew its stake in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 134 shares during the last quarter. Sunbelt Securities Inc. purchased a new position in shares of Hologic during the second quarter valued at approximately $37,000. Finally, Cromwell Holdings LLC increased its position in Hologic by 330.2% during the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 416 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Performance

HOLX stock traded down $1.41 during midday trading on Monday, reaching $70.29. 3,100,719 shares of the company's stock traded hands, compared to its average volume of 2,138,960. Hologic, Inc. has a 52-week low of $69.46 and a 52-week high of $84.67. The stock has a market cap of $15.95 billion, a P/E ratio of 21.11, a PEG ratio of 2.32 and a beta of 0.97. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The stock's 50-day moving average is $75.61 and its 200 day moving average is $78.53.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts' consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. During the same period last year, the firm earned $0.89 EPS. Hologic's revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm's stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares of the company's stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.75% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Royal Bank of Canada upped their price target on Hologic from $86.00 to $89.00 and gave the stock a "sector perform" rating in a research note on Tuesday, November 5th. Mizuho decreased their price target on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Tuesday, November 5th. UBS Group upped their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Evercore ISI raised their target price on shares of Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a research note on Tuesday, October 1st. Finally, William Blair reissued an "outperform" rating on shares of Hologic in a research report on Monday. Seven analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Hologic currently has an average rating of "Moderate Buy" and a consensus target price of $88.92.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.